Class of Stock [Axis] Class A common stock, par value $0.0001 per share Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Product and Service [Axis] Product [Member] Service [Member] License Royalty and Other [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Series A Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Pledging Purpose [Axis] Letter of Credit [Member] Segments [Axis] Cell Therapy [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Two Customers [Member] Three Customers [Member] Customer One [Member] Revenue Benchmark [Member] Customer Two [Member] Long-Lived Tangible Asset [Axis] Furniture and Fixtures [Member] Equipment [Member] Computer Equipment [Member] Software Development [Member] Leasehold Improvements [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Restricted Stock Units (RSUs) [Member] Market Condition Stock Units [Member] Warrant [Member] Convertible Debt Securities [Member] Asset Acquisition [Axis] Sequence LifeScience Inc [Member] Business Combination, Contingent Consideration, Type [Axis] Contingent Stock Consideration [Member] Short-Term Debt, Type [Axis] Convertible Promissory Notes [Member] Unsecured Senior Convertible Notes [Member] December 2025 Promissory Note [Member] December 2025 Convertible Note [Member] Class of Warrant or Right [Axis] May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] RWI Bridge Warrants [Member] KTL Warrants [Member] Sponsors Warrants [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Lender Name [Axis] Yorkville [Member] KTL Secured Promissory Note [Member] KTL Warrant [Member] Common Class A [Member] KTL Secured Promissory Note One [Member] Counterparty Name [Axis] Equity Purchase Agreement [Member] Measurement Input Type [Axis] Measurement Input, Credit Spread [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input Optional Redemption [Member] Measurement Input Optional Redemption Upon Default [Member] Measurement Input Default [Member] Measurement Input Optional Conversion [Member] Measurement Input Dissolution [Member] Measurement Input Equity Volatility [Member] Derivative Instrument [Axis] Bifurcated Derivative [Member] Measurement Input, Maturity [Member] Measurement Input Penalty Dividend Rate [Member] Measurement Input Probability of Dissolution [Member] Laboratory and Production Equipment [Member] Machinery, Equipment and Fixtures [Member] Biobanking [Member] Finite-Lived Intangible Assets by Major Class [Axis] Developed Technology Rights [Member] Customer Relationships [Member] Trademarks and Trade Names [Member] Reacquired Rights [Member] Credit Facility [Axis] 2025 Convertible Note [Member] 2025 Promissory Note [Member] Unsecured Senior Convertible Note [Member] CEO Promissory Note [Member] CV Starr Bridge Loan Net of Discount [Member] RWI Bridge Loan Net of Discount [Member] Debt Instrument [Axis] December 2025 First Tranche Warrants [Member] Long-Term Debt, Type [Axis] December 2025 Second Tranche Warrants [Member] Advisor Warrants [Member] Advisor Warrant [Member] Loan Agreement [Member] Title and Position [Axis] Chairman and Chief Executive Officer [Member] C.V. Starr Co Inc [Member] Forbearance Agreement [Member] Vesting [Axis] Tranche Two Warrant [Member] Bridge Loan [Member] Initial Loan [Member] Additional Loan [Member] Tranche One Warrant [Member] Initial and Second Tranche [Member] Resorts World Inc Pte Ltd [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Merchant Cash Advance Agreement [Member] Intellectual Property [Member] Asset Purchase Agreement [Member] Office Manufacturing and Laboratory Space [Member] Geographical [Axis] Florham Park New Jersey [Member] Business Combination [Axis] Legacy Celularity [Member] HLI Cellular Therapeutics LLC and Anthrogenesis [Member] Legacy Celularitys [Member] Palantir Technologies Inc [Member] Master Subscription Agreement [Member] Statement Of Income Location Balance [Axis] Software Cease Use Costs [Member] License Agreement [Member] Litigation Case [Axis] Evolution [Member] TCW Global [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Target CW Global [Member] Legal Entity [Axis] Hackensack Meridian Health [Member] October Two Thousand Twenty Five Purchase Agreement [Member] October Two Thousand Twenty Five Warrant [Member] October 2025 One Warrant [Member] October 2025 Financing [Member] Measurement Input, Expected Term [Member] October 2025 [Member] Sale of Stock [Axis] Private Placement [Member] January 2024 PIPE Warrants [Member] 2024 Warrant Repricing [Member] Investor Rights Agreement [Member] Dragasac Limited [Member] 2024 Warrants [Member] 2020 Warrants [Member] Securities Purchase Agreement [Member] June 2025 PIPE [Member] RWI Forbearance Agreement [Member] Starr Forbearance Agreement [Member] March 2023 Loan Warrants [Member] June 2023 Loan Warrants [Member] Warrants [Member] June 2023 Warrants [Member] July 2025 PIPE Warrants [Member] Lim Kok Thay [Member] December 2025 First Tranche Warrants [Member] December 2025 Second Tranche Warrants [Member] Public Warrants [Member] Sponsor Warrants [Member] May 2022 Private Investment in Public Equity Warrants [Member] March 2023 Private Investment in Public Equity Warrants [Member] March 2023 Private Investment in Public Equity Warrants, Modified [Member] April 2023 Registered Direct Warrants [Member] April 2023 Registered Direct Warrants Modified [Member] May 2023 Private Investment in Public Equity Warrants [Member] May 2023 Private Investment in Public Equity Warrants Modified [Member] June 2023 Loan RWI BridgeWarrants [Member] July 2023 Registered Direct Warrants [Member] January 2024 REI Bridge Warrants [Member] January 2024 REI Bridge Warrants Tranche Two [Member] March 2024 REI Bridge Warrants [Member] November 2024 Purchaser Warrants [Member] November 2024 Placement Agent Warrants [Member] February 2025 Binding Term Sheet [Member] July 2025 BindingTermSheet [Member] Faithstone Strategic Advisory Warrants [Member] October 2025 Consultant Warrants Tranche One [Member] October 2025 Consultant Warrants Tranche Two [Member] October 2025 Consultant Warrants Tranche Three [Member] October 2025 Warrants [Member] October 2025 Placement Agent Warrants [Member] December 2025 Waiver Warrants [Member] Plan Name [Axis] 2021 Equity Incentive Plan [Member] Award Type [Axis] Strategic Advisory Agreement [Member] Measurement Input, Share Price [Member] May Warrants [Member] Measurement Input, Exercise Price [Member] Share-Based Payment Arrangement, Tranche One [Member] Market Condition Stock Unit [Member] Consultant Agreement [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] 2021 and 2017 Equity Incentive Plan [Member] 2021 Plan [Member] 2017 Plan [Member] Share Based Compensation Award Tranche Four [Member] Cost Of Sale [Member] Research And Development Expenses [Member] Selling General And Administrative Expense [Member] October 2025 Consultant Warrants Market Condition Award [Member] Regeneron Research Collaboration Services Agreement [Member] Regeneron Services Agreement [Member] Bio Cellgraft [Member] License Revenue [Member] Income Tax Jurisdiction [Axis] United States Federal and State [Member] State of New Jersey Income Tax [Member] Degenerative Disease [Member] Related Party Transaction [Axis] Dr. Robert Hariri [Member] Amended and Restated Employment Agreement [Member] C.V. Starr Loan [Member] Senior Secured Loan Agreement [Member] Employment of Immediate Family Member [Member] Technology Services Agreement [Member] Purchase Agreement [Member] Defeye, Inc. [Member] Series A Convertible Preferred Stock [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Opinion [Text Block] Auditor Name Auditor Location Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Assets Current assets: Cash and cash equivalents Accounts receivable, net of allowance of $7,647 and $6,294 as of December 31, 2025 and 2024, respectively Inventory Prepaid expenses and other current assets Total current assets Property and equipment, net Goodwill Intangible assets, net Right-of-use assets - operating Restricted cash Inventory, net of current portion Other long-term assets Total assets Liabilities and Stockholders’ (Deficit) Equity Current liabilities: Accounts payable Accrued expenses and other current liabilities Short-term debt Short-term license obligation Deferred revenue Preferred stock redemption liability Derivative liability Total current liabilities Deferred revenue, net of current portion Noncurrent debt - related parties Noncurrent acquisition - related contingent consideration Noncurrent lease liabilities - operating Warrant liabilities Long-term license obligation Deferred income tax liabilities Other liabilities Total liabilities Commitments and contingencies (Note 15) Stockholders’ (deficit) equity Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 1,732,084 and 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively Common Stock, $0.0001 par value, 730,000,000 shares authorized; 28,837,787 and 22,546,671 shares issued and outstanding as of December 31, 2025 and 2024, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders’(deficit) equity Total liabilities and stockholders’(deficit) equity Statement of Financial Position [Abstract] Accounts receivable, allowance Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Net revenues Total revenues Operating expenses Cost of revenues (excluding amortization of acquired intangible assets) Cost of revenues Research and development Selling, general and administrative Change in fair value of contingent consideration liability Amortization of acquired intangible assets Total operating expenses Loss from operations Other income (expense): Interest income Interest expense Change in fair value of warrant liabilities Change in fair value of derivative liability Change in fair value of debt Loss on debt extinguishment Amortization of licensing obligation premium Loss on issuance of convertible notes with warrants Impairment of preferred stock investment Compliance fees and other expense, net Total other expense Loss before income taxes Income tax expense (benefit) Net loss Deemed dividend relating to inducement of Dragasac warrants Paid-in kind preferred stock dividend Net loss attributable to common shareholders Net loss per share - basic Net loss per share - diluted Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Net loss Change in fair value of debt due to change in credit risk Comprehensive loss Balances Balance, shares Issuance of common stock and warrants in PIPE Offering, net of offering expenses Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares Issuance of common stock to Yorkville for debt extension and SEPA commitment fee Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares Issuance and modification of warrants to C. V. Starr Exercise of stock options Exercise of stock options, shares Retirement of shares in connection with reverse stock split Retirement of shares in connection with reverse stock split, shares Issuance of common stock to Palantir as consideration for settlement agreement Issuance of common stock to Palantir as consideration for settlement agreement, shares Stock-based compensation expense Reclassification of warrants from liability classified to equity classified Change in FV of debt Vesting of restricted stock units Vesting of restricted stock units, shares Tax withholding on vesting of restricted stock units Tax withholding on vesting of restricted stock units, shares Conversion of unsecured senior convertible note Conversion of Madison Global Partners convertible note, shares Issuance of common stock as compensation expense Issuance of common stock as compensation expense, shares Director fees paid with restricted stock units Director fees paid with restricted stock units, shares Exercise of common stock warrants by Dragasac Exercise of common stock warrants by Dragasac, shares Dragasac Warrant Issuance Inducement Issuance of common stock consideration shares to Yorkville in connection with Side Letter Issuance of common stock consideration shares to Yorkville in connection with Side Letter, shares Issuance of common stock in connection with settlement of debt Issuance of common stock in connection with settlement of debtt, shares Conversion of Yorkville convertible note Conversion of Yorkville convertible note, shares Issuance of common stock in exchange for consulting services Issuance of common stock in exchange for consulting services, shares Issuance of warrants for Strategic Advisory Services Issuance of common stock due to Strategic Advisory Agreement Issuance of common stock due to Strategic Advisory Agreement, shares Issuance of warrants to preferred stockholders in consideration of forbearance agreement Issuance of December 2025 Warrants Reclassification of RWI Bridge warrants from liability classified to equity classified Reclassification of November 2024 Purchaser and Placement Agent warrants from liability classified to equity classified Reclassification of liability classified KTL Warrants to equity classified Issuance of RWI warrants and extinguishment of promise to issue warrants liability Sale and issuance of common stock in private placement Sale and issuance of common stock in private placement, shares Sale and issuance of common stock and warrants in private placement Sale and issuance of common stock and warrants in private placement, shares Issuance of preferred stock with warrants in PIPE Offering (net of transaction costs of $210 and bifurcated derivative liability of $157) Issuance of preferred stock with warrants in PIPE Offering, shares Settlement of contingent stock consideration liability Settlement of contingent stock consideration liability, shares Redemption of preferred stock Redemption of preferred stock, shares Paid-in kind preferred stock dividends Balances Balance, shares Statement of Stockholders' Equity [Abstract] Net of transaction costs Bifurcated derivative liability Statement of Cash Flows [Abstract] Cash flow from operating activities: Adjustments to reconcile net loss to net cash used in operations: Depreciation and amortization Non cash lease expense Gain on amortization of licensing obligation Provision for credit losses Change in fair value of warrant liabilities Change in fair value of derivative liability Inventory reserve for obsolescence Inventory impairment Impairment of preferred stock investment Loss on issuance of common stock to Yorkville in connection with the Side Letter Loss on issuance of common stock in connection with the settlement of debt Issuance of warrants for Strategic Advisory Agreement Issuance of common stock due to Strategic Advisory Agreement Loss on issuance of convertible note with warrants Issuance of warrants to preferred stockholders in consideration of forbearance agreement Gain on forgiveness of interest Share-based compensation expense Director fees paid with RSU’s Issuance of common stock to Palantir as consideration for settlement agreement Issuance of common stock to Yorkville for debt extension and SEPA commitment fee Issuance of common stock for consulting expense Change in fair value of contingent stock consideration Loss on extinguishment of debt Change in fair value of debt Non cash interest expense Other, net Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other assets Accounts payable Accrued expenses and other liabilities Accrued R&D software Lease liabilities Deferred income tax liabilities Deferred revenue Net cash used in operating activities Cash flow from investing activities: Capital expenditures Rebound asset acquisition Proceeds from Sanuwave convertible note receivable Net cash provided by investing activities Cash flow from financing activities: Transaction costs related to the issuance of promissory notes with warrants Proceeds from Issuance of promissory notes with warrants Proceeds from warrants and short-term debt - related parties Proceeds from issuance of short-term debt - unaffiliated Repayment of short-term debt - unaffiliated Payment of SEPA commitment fee Proceeds from the sale of common stock in June 2025 PIPE Proceeds from the sale of common stock and warrants in July 2025 PIPE Proceeds from related party note with KTL Warrant Proceeds from the exercise of stock options Cash proceeds from merchant cash advance Repayment of merchant cash advance Proceeds from the exercise of warrants by Dragasac Repayment of short-term debt - related party Proceeds from issuance of preferred stock with warrants in PIPE Offering Transaction costs from issuing of preferred stock with warrants in PIPE Offering Tax withholding on vesting of restricted stock units Repayment of related party notes Net cash provided by financing activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Supplemental non-cash investing and financing activities: Residual fair value of warrants issued with promissory notes Reclass of redemption value of preferred shares from equity to liability Conversion of unsecured senior convertible note Conversion of Yorkville convertible note Common stock issued for short-term debt conversion Exchange of IP assets for license obligation Preferred stock received for product purchase credits Property and equipment included in accounts payable and accrued expenses Reclassification of RWI Bridge warrants from liability classified to equity classified Reclassification of November 2024 Purchaser and Placement Agent warrants from liability classified to equity classified Reclassification of KTL Warrants from liability classified to equity classified Issuance of RWI warrants and extinguishment of promise to issue warrants liability Deemed dividend relating to inducement of Dragasac warrants Settlement of contingent stock consideration liability Paid-in kind preferred stock dividends Fair value of bifurcated derivative liability associated with Preferred Stock issuance Modification of C.V. Starr warrants in connection with forbearance Issuance of RWI warrants in connection with forbearance Inventory acquired in connection with Rebound asset acquisition Reclassification of warrants from liability classified to equity classified Assumption of short-term debt - unaffiliated by related party Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Accounting Policies [Abstract] Nature of Business Summary of Significant Accounting Policies Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Asset Acquisition Fair Value Disclosures [Abstract] Fair Value of Financial Assets and Liabilities Inventory Disclosure [Abstract] Inventory Prepaid Expenses And Other Current Assets Prepaid Expenses and Other Current Assets Property, Plant and Equipment [Abstract] Property and Equipment, Net Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets, Net Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Debt Disclosure [Abstract] Debt Transfers and Servicing [Abstract] Transfers of Financial Assets Asset Retirement Obligation Disclosure [Abstract] Licensing Obligation Operating Leases Operating Leases Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Equity Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Revenue from Contract with Customer [Abstract] Revenue License And Distribution Agreements License and Distribution Agreements Retirement Benefits [Abstract] Benefit Plan Income Tax Disclosure [Abstract] Income Taxes Segment Reporting [Abstract] Segment Information Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Basis of Presentation Reclassification Use of Estimates Fair Value Measurements Cash and Cash Equivalents Restricted Cash Accounts Receivable Inventory Property and Equipment Impairment of Long-Lived Assets Asset Acquisitions In-Process Research and Development Goodwill Warrant Liabilities Leases Short-Term Debt – Unaffiliated Revenue Recognition Cost of Revenues Research and Development Costs Advertising and Marketing Costs Patent Costs Stock-Based Compensation Comprehensive Loss Income Taxes Equity Method Investments Net Loss per Share Segment Information Concentrations of Credit Risk and Significant Customers Recently Issued Accounting Pronouncements Recently Adopted Accounting Pronouncements Schedule of Property and Equipment Estimated Useful Life Schedule of Potentially Dilutive Securities Schedule of Purchase Price Allocated to Acquired Assets Business Combination, Contingent Consideration [Table] Business Combination, Contingent Consideration [Line Items] Schedule of Financial Assets and Liabilities Measures at Fair Value Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis Schedule of Convertible Note Valuation Model Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis Schedule of Significant Inputs for Sponsor Warrants Schedule of Derivative Liabilities Measured on a Recurring Basis Schedule of Bifurcated Derivative Monte Carlo Valuation Model Schedule of Major Classes of Inventories Schedule of Inventory Reserves Schedule of Prepaid Expenses and Other Current Assets Schedule of Property and Equipment, Net Schedule of Carrying Value of Goodwill Schedule of Intangible Assets, Net Schedule of Aggregate Amortization Expense Related To Intangible Assets Schedule of Accrued Expenses and Other Current Liabilities Schedule of Debt Schedule of Licensing Obligation Schedule of Lease Costs Schedule of Cash Activity Related to the Lease Liabilities Schedule of Future Minimum Payments under Operating Leases Summary of the Warrants Schedule of Weighted Average Grant Fair Value of Stock Options Using Black-Scholes Option-Pricing Model Schedule of Stock Option Activity Schedule of Warrants Purchase Agreement Schedule of Activity Related to RSU Stock-Based Payment Awards Schedule of Stock-based Compensation Expense Schedule of Disaggregated Revenue by Product and Services Schedule of Changes in Deferred Revenue from Contract Liabilities Schedule of Current and Deferred Tax Provision Schedule of Reconciliation of the U.S federal statutory income tax and effective income tax rate Schedule of Deferred tax assets and liabilities Schedule of Unrecognized Tax Benefits Schedule of Financial Information by Segment Net loss Net cash used in operating activities Retained Earnings (Accumulated Deficit) Working capital deficit Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment expected useful lives Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Reclassified from contingent consideration Accounts receivable balance, net of allowance for credit losses Operating segments Goodwill impairment Contracted storage periods Over time for a period Advertising and marketing costs Instrument-specific credit risk income Instrument-specific credit risk loss Income tax examination likelihood settlement Number of segments Concentration risk, percentage Asset Acquisition [Table] Asset Acquisition [Line Items] Cash payment Contingent consideration Total consideration Inventory Total assets acquired Asset Acquisition, Price of Acquisition, Expected Upfront payment Monthly milestone payments Prior payment to related party Accured milestone payments Increase (Decrease) in Other Accrued Liabilities Asset Acquisition, Contingent Consideration, Liability Accrued expenses and other current liabilities Purchase price contingent consideration Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Acquisition-related contingent consideration obligations Contingent stock consideration Short-term debt - Yorkville Short-term debt - unsecured senior convertible notes December 2025 Convertible Note December 2025 Promissory Note Warrant liability - July 2023 Registered Direct Warrants Warrant liability - April 2023 Registered Direct Warrants Warrant liability - May 2022 PIPE Warrants Warrant liability - November 2024 Purchaser Warrants Warrant liability - November 2024 Placement Agent Warrants Warrant liability - Sponsor Warrants Warrant liability - Public Warrants Bifurcated embedded derivative – Series A Preferred Stock Total fair value liabilities Beginning balance Net transfers in to (out of) Level 3 Purchases, settlements and other net Fair value adjustments Ending balance Fair Value, by Balance Sheet Grouping [Table] Number of stock issued Contingent stock consideration liability Fair value of the contingent stock consideration obligation Fair value of convertible note Conversion of debt into common shares Unsecured convertible note Fair value of promissory note Debt issued Warrants to purchase aggregate shares Annual interest rate Fair value price per share Warrant term Sale of Stock, Consideration Received on Transaction Beginning balance Net transfers into (out of) Level 3 Purchases, settlements and other net Fair value adjustments Ending balance Line of Credit Facility [Table] Line of Credit Facility [Line Items] Beginning balance Principal repayments Issuance of unsecured senior convertible notes, net of fair value adjustment Issuance of convertible promissory note Issuance of unsecured senior convertible notes, net of fair value adjustment Conversion of debt into common shares Fair value adjustment through earnings Fair value adjustment through accumulated other comprehensive income Ending balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Common share price Common share price Term (years) Debt, measurement input Fair value of warrant liabilities, Beginning Balance Issuance of RWI Bridge Warrants in connection with RWI binding term sheet Issuance of KTL Warrants in connection with the KTL Note Reclassification of November 2024 Purchaser and Placement Agent warrants to equity Reclassification of RWI Bridge warrants to equity Reclassification of the KTL Warrants to equity Gain recognized in earnings from change in fair value Fair value of warrant liabilities, Ending Balance January 2024 Bridge Loan - Tranche #2 warrant issuance November 2024 Purchaser warrant issuance November 2024 Placement Agent warrant issuance Reclassification of warrants from liability classified to equity classified Exercise price Warrants measurement input Term (years) Equity classified warrants Warrants outstanding measurement input Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Exercise price percent Exercise Price Derivative liabilities, beginning balance Fair value of derivative liability associated with Series A Preferred Stock at issuance Change in fair value of bifurcated embedded derivative Derivative liabilities, ending balance Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Series A Preferred Stock Valuation Probability of dissolution Raw materials Work in progress Finished goods Inventory, gross Less: inventory reserves Inventory, net Beginning balance Utilization of inventory reserve Ending balance Inventory impairment charge Schedule Of Prepaid Expenses And Other Current Assets Prepaid clinical expenses Prepaid insurance expense Other Prepaid expenses and other current assets Property and equipment Less: Accumulated depreciation and amortization Property and equipment, net Depreciation Intangible Asset, Indefinite-Lived [Table] Indefinite-Lived Intangible Assets [Line Items] Goodwill Balance Goodwill Recognized Goodwill Impairment Goodwill Ending Balance Intangible Asset, Finite-Lived [Table] Finite-Lived Intangible Assets [Line Items] Amortizable intangible assets Estimated useful lives Less: Accumulated amortization Amortizable intangible assets, net Acquired IPR&D product rights Estimated useful lives 2026 2027 2028 2029 2030 Thereafter Amortization expense Goodwill, impairment loss Amortization expense for intangible assets Impairment of intangible assets Accrued clinical trial expense Accrued professional fees Accrued wages, bonuses, commissions and vacation Accrued interest Accrued compliance fee Accrued vendor expenses Accrued royalties - Sequence Acquisition-related contingent consideration Vendor settlements Other current liabilities Total accrued expenses and other current liabilities Total short-term debt - unaffiliated Total debt - related parties Total debt Short-term debt – related parties Long-term debt – related parties Short-Term Debt [Table] Short-Term Debt [Line Items] Number of warrant issued Incurred transaction cost Fair value adjustment of warrants Other expenses Principal amont Interest rate Maturity date Conversion price per share Fair value of the debt Maximum advance amount Original issue discount Increase in bearing interest Minimum required daily volume weighted average price Percentage of conversion on outstanding common stock Percentage of beneficial ownership limitation Debt instrument default interest rate Original issue discount Shares issued upon note conversion value Debt accrued interest Shares issued upon note conversion Debt Default, Short-Term Debt, Amount Common stock issued pursuant to short-term debt maturity extension, shares Accrued interest Notes and purchaser warrants principal amount Proceeds from notes and purchaser warrants Gross proceeds Floor price Warrant term (years) Percentage of cash fee equal to aggregate proceeds Percentage of exercise price equal to offering price Recognized loss Fair value of conversion of debt Debt instrument contribution amount Default rate Pre-paid advance maturity period Interest expense Original issue discount Effective percentage in event of default Purchase price of per share Share issued purchased price Fall in cash and cash equivalents Variable interest rate Warrant expiration date Percentage of changes in cash flow Debt instrument, unamortized discount Payment of debt Forgiveness of accrued interest Short-term debt - related parties Original issue discount amount Interest rate during period in event of default Discount on warrant amount Percentage of partial liquidating damages on purchase price Percentage of partial liquidating damages on subscription amount Daily interest accruing rate Fair value of notes Interest expense Balance owed due amount Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Aggregate purchase amount Proceeds from cash Repaid in weekly installments Repayments of debt Aggregate receivables Cash proceeds Secured borrowing liability Short-term license obligation Long-term license obligation  Total license obligation Debt principal amount Accrued paid in net Debt instrument, discount Royalty purchase price percentage Intellectual property quarterly installment Schedule Of Lease Costs Operating lease cost Variable lease cost Total operating lease cost Schedule Of Cash Activity Related To Lease Liabilities Operating cash flows from operating leases 2026 2027 2028 2029 2030 Thereafter Total lease payments Less imputed interest Total Rent expense Operating lease expiry year Lessee, Operating Lease, Option to Extend Weighted average remaining lease term Weighted average discount rate Loss Contingencies [Table] Loss Contingencies [Line Items] StatementOfIncomeLocationBalanceAxis [Axis] Contingent consideration Payments for master subscription agreement Payment subscription period Business Exit Costs Payments for legal settlements Stock Issued During Period, Shares, New Issues Accrued research and development software Upfront fee Annual maintenance fee Clinical and regulatory milestones License agreement period Sale of biomaterial products amount Affiliate costs Amount owned from other party Plaintiff, description Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of shares Expiration date Warrants outstanding Exercise per share price (in Dollars per share) Number of warrants repriced Warrants maturity date Stock, Class of Stock [Table] Class of Stock [Line Items] Common stock shares outstanding Common stock shares issued Common stock, voting rights Dividend rate Preferred stock, conversion Conversion price Preferred stock, limitations on conversion Redemption of preferred stock, shares Redemption of preferred stock Shares issued Proceeds from warrant exercises Dividend yield Expected term Expected volatility Risk-free interest rate Preferred stock stated value Fair value of warrant Preferred stock, discount Associated embedded derivative Legal fees Other expense Purchase and sale of shares Proceeds from sale of private placement Warrants and rights outstanding, expire date Proceeds from private placements Fair value of warrant modification Percentage of partial liquidating damages Damages sought, value Net loss available to common stockholders Number of warrant shares Debt Instrument, Unamortized Discount Debt Instrument, Maturity Date Issue of warrants liability Number of share issue Share price Exercise price Debt doiscount percentage Loss on fair value of warrants Transaction costs Payments of stock issuance costs Stock price Consideration shares of common stock Sale of stock, maximum average daily traded amount (in percent) Sale of stock, percentage based on volume weighted average price Cash due diligence fee Commitment fee in shares Line of credit percentage Expected term (in years) Expected dividend yield Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Options beginning balance Weighted Average Exercise Price, beginning balance Weighted Average Contract Term Aggregate Intrinsic Value Options Granted Weighted Average Exercise Price, Granted Options Exercised Weighted Average Exercise Price, Exercised Options Forfeited Weighted Average Exercise Price, Forfeited Options ending balance Weighted Average Exercise Price, ending balance Aggregate Intrinsic Value Options Vested and expected to vest Weighted Average Exercise Price, Vested and expected to vest Weighted Average Contract Term Vested and expected to vest Aggregate Intrinsic Value Vested and expected to vest Options Exercisable Weighted Average Exercise Price, Exercisable Weighted Average Contract Term Exercisable Aggregate Intrinsic Value Exercisable Options outstanding Options outstanding including awards Warrant shares Warrant exercise price Vesting conditions Number of Shares, Outstanding beginning balance Weighted Average Grant Date Fair Value,Outstanding beginning balance Number of Shares, Granted Weighted Average Grant Date Fair Value, Granted Number of Shares, Vested Weighted Average Grant Date Fair Value, Vested Number of Shares, Forfeited Weighted Average Grant Date Fair Value, Forfeited Number of Shares, Outstanding ending balance Weighted Average Grant Date Fair Value, Outstanding ending balance ScheduleOfStockBasedCompensationExpenseTable [Table] Stock-based compensation expense Director fees paid with RSU's Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares issued for future issuance automatic increase period Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Weighted average grant-date fair value of stock options granted Stock based compensation expense Aggregate intrinsic value, stock option exercised Unrecognized compensation cost for options issued Estimated weighted-average amortization period Fair value of the common stock upon issuance Compensation expense due to warrants Dividend rate Award vesting period Vesting percentage Unrecognized compensation cost Number of shares granted Number of shares forfeited Outstanding shares warrants fair value Stock based compensation Stock based compensation reaining term Fair value of the performance condition Market condition price Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Beginning Balance Deferral of revenue Recognition of unearned revenue Ending Balance Deferred revenue current Unearned revenue Deferred revenue LicenseAndDistributionAgreementsTable [Table] Nonrefundable up-front payment Service agreement term License agreement notice period Deferred revenue Revenues deferred revenue deferred revenue License revenue recognized Gross sales of licensed products Contributions made to the plan Federal State Total current income tax expense Federal State Total deferred tax expense Total income tax expense Federal statutory income tax rate Federal statutory income tax rate State income taxes, net of federal benefits State income taxes, net of federal benefits rate Change in valuation allowance Change in valuation allowance rate Nontaxable/non-deductible items: Interest accretion expense Change in valuation allowance rate Mark to market warrant Mark to market warrant rate Other permanent items Other permanent items rate Effective income tax rate Net operating loss carryforwards Research and development tax credit carryforwards Stock-based compensation expense Intangible assets Deferred revenue Capitalized research and development IRC Section 163j interest Other Total deferred tax assets Intangible assets Total deferred tax liabilities Valuation allowance Net deferred tax liabilities Balance beginning Decrease related to current year tax provisions Balance ending Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Line Items] Net operating loss carryforwards Operating loss carryforwards expiration year Tax credit carryforwards Valuation allowance increased amount Unrecognized tax benefits Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Net revenues Cost of revenues (excluding amortization of acquired intangible assets) Direct expenses Segment contribution Other general and administrative expenses Amortization Loss from operations Other expenses Loss before income taxes Indirect expenses Amortization Total indirect expenses Number of operating segments Assets Related Party Transaction [Table] Related Party Transaction [Line Items] Accrued expenses Securities purchase agreement date Unpaid base salary Net proceeds from offerings of equity securities Bonus program effective date Percentage of unpaid base salary Percentage of base salary Annual rate of base salary Loan interest rate Debt instrument maturity date Loan agreement Warrants purchase Long-Term Debt, Gross Class of Warrant or Right, Exercise Price of Warrants or Rights Accrued paid-in kind interest Royalty price percentage Royalty expense Licensing obligation Licensing obligation premium Amortization of licensing obligation Base salary Revenue Accounts receivable Stock issuance Equity fair value Impairment in preferred stock investment Subsequent Event [Table] Subsequent Event [Line Items] Aggregate consideration payable description Repayments of Short-Term Debt Shares exchanged for debt Original principal amount Debt instrument, interest rate percentage Outstanding principal percentage Accrues interest rate percentage Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share Class A common stock, par value $0.0001 per share. Non cash lease expense. Amortization of licensing obligation. Gain on amortization of licensing obligation. Operating income costs and expenses. Change in fair value of debt. Other nonoperating income expenses. Deemed dividend relating to inducement of warrants. Inventory reserve for obsolescence. Inventory Impairment Charge. Paid in kind preferred stock dividend. Issuance of common stock relating to debt extension and commitment fee. Loss on issuance of common stock to in connection with side letter. Issuance of common stock in connection with settlement of debt. Loss on issuance of convertible note with warrants. Issuance of warrants for consulting services. Warrant liability. Issuance of warrants for forbearance expense. Stock issued during period value for debt extension and commitment fee. Stock issued during period shares for debt extension and commitment fee. Adjustments to additional paid in capital issuance and modification of warrants. Stock issued during period value for consideration for settlement agreement. Stock issued during period shares for consideration for settlement agreement. Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified. Non cash interest expense. Issuance of common stock as consideration for settlement agreement. Gain(loss) from the forgiveness of accrued interest. Issuance of common stock as consulting expense. Change in fair value of contingent stock consideration. Increase decrease in accrued research development software expense. Stock issued during period value issuance of common stock consideration shares to in connection with side letter. Stock issued during period shares issuance of common stock consideration shares to in connection with side letter. Stock issued during period value issuance of common stock in connection with settlement of debt. Stock issued during period shares issuance of common stock in connection with settlement of debt. The increase (decrease) during the reporting period in deferred income tax liabilities. Warrants issued for consulting services. Proceeds from convertible note. Short term license lease. Proceeds from warrants and short term debt related parties. Proceeds from short term debt unaffiliated. Repayments of short term debt unaffiliated. Payment of sepa commitment fee. Issuance of equity-classified warrants. Issuance of warrants due to forbearance expense. Issuance of warrants in Barach Financing. Reclassification of liability classified warrants to equity classified. Stock issued during period value sale and issuance of common stock in private placement. Stock issued during period shares sale and issuance of common stock in private placement. Stock issued during period value sale and issuance of common stock and warrants in private placement. Stock issued during period shares sale and issuance of common stockand warrant in private placement Issuance of preferred stock with warrants in PIPE Offering. Number of shares of stock issued attributable to transactions sale and issuance of common stock and warrants in private placement. Proceeds from Issuance of promissory notes with warrants. Value of shares of stock issued attributable to settlement of contingent stock consideration liability. Number of shares of stock issued attributable to transactions exercise of stock options shares. Adjustments to additional paid in capita bifurcation of derivative liability form preferred stock. Deemed dividend relating to inducement of Dragasac warrants. Adjustments to redemption of preferred stock. Reclassification of warrants from liability classified to equity classified. Paid-in kind preferred stock dividends. Change in fair value of contingent consideration. Modification of C.V. Starr warrants in connection with forbearance. Issuance of RWI warrants in connection with forbearance. Assumption of short-term debt - unaffiliated by related party. Inventory acquired in connection with Rebound asset acquisition. Contingent consideration accrued in connection with Rebound asset acquisition. Value of shares of stock issued during the period director fees paid with restricted stock units. Number of shares of stock issued during the period vesting of restricted stock units Redemption of preferred stock. Exchange of IP assets for debt. Preferred stock received for product purchase credits. Settlement of contingent stock consideration liability. Bifurcation of derivative liability from preferred stock. Proceeds from the issuance of common stock to dragasac as consideration for inducement agreement. Reclassification of warrants from liability classified to equity classified. Change In fair value of debt due to change in credit risk net of tax. Vesting of restricted stock units. License Royalty and Other [Member] Schedule of Estimated Useful Lives [Table Text Block] Asset Acquisitions [Policy Text Block] Cell Therapy [Member] Warrants Liabilities [Policy Text Block] Short-term Debt [Policy Text Block] Unsecured Senior Convertible Notes [Member] Contracted storage periods. Payment plans for customer to pay over time period. Patent Costs [Policy Text Block] Instrument specific credit risk loss. Instrument specific credit risk income. Market Condition Stock Units [Member] Disclosure of accounting policy related to allowance for credit losses. Three Customers [Member] Two Customers [Member] Customer One [Member] Customer Two [Member] Recently Adopted Accounting Pronouncements [Policy Text Block] Sequence LifeScience Inc [Member] Upfront payment. Monthly milestone payments. Prior payment to related party. Net sales percentage. Accured milestone payments. HLI Cellular Therapeutics LLC and Anthrogenesis [Member] Legacy Celularitys [Member] Payments for master subscription agreement. Palantir Technologies Inc [Member] Master Subscription Agreement [Member] Payment subscription period. Software Cease Use Costs [Member] Accrued research and development software. Clinical and regulatory milestones. License Agreement [Member] Upfront fee. Annual maintenance fee. License agreement notice period. Sale of biomaterial products amount. Evolution [Member] TCW Global [Member] Hackensack Meridian Health [Member] Target CW Global [Member] Purchase price contingent consideration. Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory. Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory assets. Warrant liability registered direct warrants two. Warrant liability registered direct warrants. Warrant liability private investment in public equity warrants. Warrant liability public warrants. Contingent stock consideration. Short-term debt unsecured senior convertible notes. Warrant liability purchaser warrants. Warrant liability placement agent warrants. Warrant liability sponsor warrants. Contingent Stock Consideration [Member] Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block] Yorkville [Member] Fair value measurement with unobservable inputs reconciliation convertible promissory note. Issuance of unsecured senior convertible notes, net of fair value adjustment. Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares. Fair value adjustment through earnings. Fair value adjustment through accumulated other comprehensive income. Issuance of convertible notes net of fair value adjustment. Fair value measurement with unobservable inputs reconciliation settlement of debt in connection with issuance of common stock. Convertible Promissory Notes [Member] Schedule Of Inventory Current And Noncurrent [Table Text Block] Inventory raw materials current and noncurrent. Inventory work in progress current and noncurrent. Inventory finished goods current and noncurrent. Inventory gross current and noncurrent. Inventory reserve current and noncurrent. Inventory net current and noncurrent. Schedule Of Activity In Inventory Reserves [Table Text Block] Provision for obsolete inventory. Prepaid Expenses And Other Current Assets Disclosure [Text Block] Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block] Prepaid clinical expense. Schedule of Intangible Assets Net [Table Text Block] Reacquired Rights [Member] Indefinite lived intangible assets amortization method. October Two Thousand Twenty Five Purchase Agreement [Member] October Two Thousand Twenty Five Warrant [Member] Two Thousand Twenty Four Warrants [Member] June 2025 PIPE [Member] Accrued clinical trial expense. Accruals for construction in progress. Accrued compliance fee. October 2025 Financing [Member] Accrued vendor settlements and advances. Accrued vendor expenses. May Warrants [Member] Short term debt unaffiliated. Short-term debt - related parties. Debt. Pre Paid Advance Agreement [Member] Pre paid advance issued discount percentage. Line of credit increase in interest rate during period in event of default. Issuance of common stock minimum option price per share. Debt Instrument Per Diem Interest Amount. Equity Purchase Agreement [Member] Convertible Promissory Note Discount Percentage. Minimum required daily volume weighted average price. Percentage of conversion on outstanding common stock. Percentage of beneficial ownership limitation. Debt instrument default interest rate October 2025 [Member] January 2024 PIPE Warrants [Member] Proceeds from private placements. Number Of Warrants Repriced. 2024 Warrant Repricing [Member] Fair Value Of Warrant Modification Incremental For Equity Issuance Cost. Percentage of partial liquidating damages on subscription amount. Investor Rights Agreement [Member] Dragasac Limited [Member] Daily Interest Accruing Rate. Two Thousand Twenty Warrants [Member] Securities Purchase Agreement [Member] Class of warrant or righst expiration date. RWI Forbearance Agreement [Member] Starr Forbearance Agreement [Member] March 2023 Loan Warrants [Member] C.V. Starr Co Inc [Member] June 2023 Loan Warrants [Member] Warrants [Member] Resorts World Inc Pte Ltd [Member] Floor price. Debt conversion original debt accrued interest amount. June 2023 Warrants [Member] Notes and purchaser warrants principal amount. Proceeds from notes and purchaser warrants. July 2025 PIPE Warrants [Member] Percentage of cash fee equal to aggregate proceeds. Percentage of exercise price equal to pffering price. Lim Kok Thay [Member] KTL Warrant [Member] Loan Agreement [Member] Chairman and Chief Executive Officer [Member] Debt instrument discount percent. Debt Instrument, Contribution Amount. CEO Promissory Note [Member] Gain loss on fair value of warrants. Debt Instrument Original Issue Discount. Debt Instrument, Interest Rate, Effective Percentage in Event of Default. Disclosure of fair value warrants liabilities measured on recurring basis. Share Issued Purchased Price. Fair value of warrants. Issuance of warrants reported at fair value. Change in fair value of warrant liability. Fall In Cash And Cash Equivalents. Forbearance Agreement [Member] Tranche Two Warrant [Member] Percentage of changes in cash flow. Short term debt related parties. Initial Loan [Member] Debt instrument discount. Debt instrument interest rate during period in event of default. Additional Loan [Member] Discount on warrant amount. Tranche One Warrant [Member] Percentage of partial liquidating damages on purchase price. Initial and Second Tranche [Member] KTL Secured Promissory Note [Member] Aggregate purchase amount. Merchant Cash Advance Agreement [Member] Royalty purchase price percentage. Asset Purchase Agreement [Member] License obligation arising from exchange of IP assets for debt. License obligation premium. Short-term licensing obligation. Long-term licensing obligation. Operating leases rent expense. Area of building. Office Manufacturing and Laboratory Space [Member] Florham Park New Jersey [Member] Legacy Celularity [Member] Operating lease expiry year. Operating lease commencement date. Initial monthly base rent. Reduction in line of credit. New line of credit. Base rental payments. Cash and Non Cash Activity Related To Lease Liabilities [Table Text Block] December 2025 First Tranche Warrants [Member] December 2025 Second Tranche Warrants [Member] Advisor Warrants [Member] December 2025 First Tranche Warrants [Member] December 2025 Second Tranche Warrants [Member] December 2025 Promissory Note [Member] Transaction costs. May 2023 Private Investment in Public Equity Warrants [Member] Measurement Input Optional Redemption [Member] Measurement Input Optional Redemption Upon Default [Member] Advisor Warrant [Member] Measurement Input Default [Member] Measurement Input Dissolution [Member] Measurement Input Optional Conversion [Member] Issuance of Rwi bridge warrants in connection with Rwi binding term sheet. Reclassification of warrants to equity. Gain loss recognized in earnings from change in fair values. Sale of stock maximum average daily traded amount percentage. Sale of stock percentage based on volume weighted average price. Sale of stock consideration cash due diligence fee. Sale of stock consideration commitment fee in shares. Reclassification of purchaser and placement agent warrants to equity. Public Warrants [Member] Sponsor Warrants [Member] May 2022 Private Investment in Public Equity Warrants [Member] Bridge loan and warrant issuance tranche two. November 2024 Purchaser warrant issuance. November 2024 Placement Agent warrant issuance. March 2023 Private Investment in Public Equity Warrants [Member] Schedule Of Fair Value Significant Inputs For Warrants Issued [Table Text Block] March 2023 Private Investment in Public Equity Warrants, Modified [Member] April 2023 Registered Direct Warrants [Member] April 2023 Registered Direct Warrants Modified [Member] June 2023 Loan RWI BridgeWarrants [Member] July 2023 Registered Direct Warrants [Member] January 2024 REI Bridge Warrants [Member] January 2024 REI Bridge Warrants Tranche Two [Member] March 2024 REI Bridge Warrants [Member] November 2024 Purchaser Warrants [Member] November 2024 Placement Agent Warrants [Member] February 2025 Binding Term Sheet [Member] May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] July 2025 BindingTermSheet [Member] Faithstone Strategic Advisory Warrants [Member] RWI Bridge Warrants [Member] October 2025 Consultant Warrants Tranche One [Member] Measurement Input Equity Volatility [Member] October 2025 Consultant Warrants Tranche Two [Member] October 2025 Consultant Warrants Tranche Three [Member] Sponsors Warrants [Member] October 2025 Warrants [Member] December 2025 Waiver Warrants [Member] Warrants Outstanding. 2021 Equity Incentive Plan [Member] Share based compensation arrangement by share based payment award number of shares issued for future issuance automatic increase period. 2017 Equity Incentive Plan [Member] 2021 and 2017 Equity Incentive Plan [Member] 2021 Plan [Member] 2017 Plan [Member] Awards with Performance Conditions [Member] Initial Tranche [Member] Second Tranche [Member] Strategic Advisory Agreement [Member] Share based compensation arrangement by share based payment award non options vested and expected to vest outstanding number. Share Based Compensation Award Tranche Four [Member] Share based compensation arrangement by share based payment award non options vested and expected to Vest outstanding weighted average exercise price. Schedule Of Bifurcated Derivative Monte Carlo Valuation Model [Table Text Block] Market Condition Stock Unit [Member] Bifurcated Derivative [Member] Measurement Input Penalty Dividend Rate [Member] Measurement Input Probability of Dissolution [Member] Contract with customer liability increase decrease for contract from business combination and deferred revenue. Unearned revenue. License and Distribution Agreements [Text Block] Service agreement term. Regeneron Research Collaboration Services Agreement [Member] Nonrefundable up-front payment. Regeneron Services Agreement [Member] Bio Cellgraft [Member] Statement of Income Location Balance [Axis] Cost Of Sale [Member] Research And Development Expenses [Member] Selling General And Administrative Expense [Member] Effective income tax rate reconciliation interest accretion expense. Effective income tax rate reconciliation mark to market warrant. Effective income tax rate reconciliation deferred true up. Deferred tax assets tax credit carryforwards research and development. Deferred tax assets startup costs. Deferred tax assets unicap. Deferred tax assets imputed interest on contingent payments. Deferred tax assets legal fee capitalization and amortization. Deferred tax assets capitalized research and development. Deferred tax assets irc section interest. Operating loss carryforwards expiration year. Segment contribution. Indirect expenses. Securities purchase agreement date. Unpaid base salary. Bonus program effective date. Percentage of unpaid base salary. Annual Rate Of Base Salary. Percentage Of Base Salary. Base salary effective date. Royalty price percentage. Licensing obligation. License obligation premium. Related party base salary. Amortization of licensing obligations. Other [Member] Laboratory and Production Equipment [Member] Machinery, Equipment and Fixtures [Member] Unsecured Senior Convertible Note [Member] CV Starr Bridge Loan Net of Discount [Member] RWI Bridge Loan Net of Discount [Member] Celeniv [Member] United States Federal and State [Member] Biobanking [Member] Degenerative Disease [Member] 2025 Convertible Note [Member] 2025 Promissory Note [Member] Pre paid advance period. Share based compensation arrangement by share based payment award equity instruments other than options released in period Share based compensation arrangement by share based payment award equity instruments other than options released in period weighted average grant date fair value. Consultant Agreement [Member] Warrants issued. Debt issuance costs. Share based payment, market price. December 2025 Convertible Note [Member] License Revenue [Member] Senior Secured Loan Agreement [Member] Dr. Robert Hariri [Member] Amended and Restated Employment Agreement [Member] C.V. Starr Loan [Member] Employment of Immediate Family Member [Member] Purchase Agreement [Member] Defeye, Inc. [Member] Short term license obligation. Long term license obligation. Amortization of licensing obligation premium. Compliance fees and other expense net. Change in fair value of debt due to change in credit risk. Adjustments to additional paid in capital issuance of warrants for strategic advisory services. Adjustments to additional paid in capital issuance of warrants to preferred stockholders in consideration of forbearance agreement. Adjustments to additional paid in capital issuance of equity classified warrants for services. Adjustments to additional paid in capital issuance of december 2025 warrants. Adjustments to additional paid in capital reclassification of liability classified KTL warrants to equity classified. Issuance of warrants for strategic advisory agreement. Issuance of warrants to preferred stockholders in consideration of forbearance agreement. Director fees paid with RSUs. Issuance of common stock for consulting expenses. accrual of redemption of preferref stock. Exchange of LP assets fro license obligation. Working capital deficit. Reclassification [Policy Text Block] Advisory Agreement Awards [Member] Direct fees paid with RSU. Reclassification of the KTL warrants to equity. KTL Warrants [Member] Income tax reconciliation interest accretion expense. Income tax reconciliation mark to market warrant. Income tax reconciliation deferred true up. Effective income tax rate reconciliation mark to market warrant rate. State of New Jersey Income Tax [Member] Other direct expenses. KTL Secured Promissory Note One [Member] Acquisition related contingent consideration. Shot term debt. October 2025 One Warrant [Member] Stock issued during period value issuance of common stock due to strategic advisory agreement Adjustments to additional paid in capital issuance of rwi warrants and extinguishment of promise to issue warrants liability Adjustments to additional paid in capital redemption of preferred stock shares Reclass of redemption value of preferred shares from equity to liability Fair value of bifurcated derivative liability associated with preferred stock issuance Reclassification of ktl warrants from liability classified to equity classified Issuance of rwi warrants and extinguishment of promise to issue warrants liability Paid in kind preferred stock dividends Fair value of contingent stock consideration obligation Utilization of inventory reserve Accrued vendor settlements Issue of warrants liability May 2023 Private Investment in Public Equity Warrants Modified [Member] October 2025 Placement Agent Warrants [Member] October 2025 Consultant Warrants Market Condition Award [Member] Strategic Advisory Agreement Common Stock [Member] Strategic Advisory Agreement Warrants [Member] Technology Services Agreement [Member] Aggregate consideration payable description Series A Convertible Preferred Stock [Member] Accrues interest rate percentage Outstanding principal percentage Deferred tax liabilities intangible assets Proceeds from the exercise of warrants by dragasac Stock issued during period shares issuance of common stock due to strategic advisory agreement. Issuance of common stock due to strategic advisory agreement. Adjustments to additional paid in capital reclassification of november 2024 purchaser and placement agent warrents from liability classified to equity classified. Adjustments to additional paid in capital reclassification of rwi bridge warrants from liability classified to equity classified. Adjustments to additional paid in capital reclassification of november purchaser and placement agent warrents from liability classified to equity classified. Reclassification of RWI bridge warrants from liability classified to equity clssified. Reclassification of november purchaser and placement agent warrants from liability classified to equity classified. Stock exchanged for debt shares. Effective income tax rate reconciliation change in valuation allowance rate. December 2025 First Tranche Warrants [Member] [Default Label] December 2025 Second Tranche Warrants [Member] [Default Label] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity OperatingIncomeCostsAndExpenses Operating Income (Loss) Other Nonoperating Expense Nonoperating Income (Expense) PaidinKindPreferredStockDividend Net Income (Loss) Available to Common Stockholders, Basic Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Stock Repurchased and Retired During Period, Value Stock Repurchased and Retired During Period, Shares Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation GainOnAmortizationOfLicensingObligation InventoryReserveForObsolescence IssuanceOfCommonStockDueToStrategicAdvisoryAgreement IssuanceOfWarrantsToPreferredStockholdersInConsiderationOfForbearanceAgreement GainsLossesOnForgivenessOfInterest IssuanceOfCommonStockAsConsiderationForSettlementAgreement IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee Increase (Decrease) in Other Operating Assets and Liabilities, Net Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable IncreaseDecreaseInDeferredIncomeTaxLiabilities Increase (Decrease) in Contract with Customer, Liability Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Payments of Debt Issuance Costs RepaymentsOfShortTermDebtUnaffiliated PaymentOfSepaCommitmentFee Payment, Tax Withholding, Share-Based Payment Arrangement Repayments of Related Party Debt Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Conversion of Stock, Amount Converted Capital Expenditures Incurred but Not yet Paid ReclassificationOfRwiBridgeWarrantsFromLiabilityClassifiedToEquityClassified ReclassificationOfNovemberPurchaserAndPlacementAgentWarrantsFromLiabilityClassifiedToEquityClassified IssuanceOfRwiWarrantsAndExtinguishmentOfPromiseToIssueWarrantsLiability SettlementOfContingentStockConsiderationLiability PaidinKindPreferredStockDividends ReclassificationOfWarrantFromLiabilityClassifiedToEquityClassified Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Inventory Disclosure [Text Block] Lessee, Operating Leases [Text Block] Inventory, Policy [Policy Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] WorkingCapitalDeficit Asset Acquisition, Consideration Transferred AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Accounts Payable and Other Accrued Liabilities, Current Liabilities, Fair Value Disclosure Receivables, Fair Value Disclosure Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares Fair Value, Net Asset (Liability) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Derivative Liability InventoryGrossCurrentAndNoncurrent InventoryReserveCurrentAndNoncurrent InventoryNetCurrentAndNoncurrent Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment IndefiniteLivedIntangibleAssetsAmortizationMethod Accrued Liabilities, Current Debt [Default Label] Debt Instrument, Increase, Accrued Interest DebtInstrumentOriginalIssueDiscount Interest Expense, Borrowings ShorttermLicensingObligation LongtermLicensingObligation Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Contract with Customer, Liability Deferred Revenue, Revenue Recognized Proceeds from Fees Received Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Federal, State and Local, Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent EffectiveIncomeTaxRateReconciliationChangeInValuationAllowanceRate Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Deferred Income Deferred Tax Assets, Other Deferred Tax Assets, Gross DeferredTaxLiabilitiesIntangibleAssets Deferred Tax Liabilities, Gross Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions Operating Loss Carryforwards